丁实，副教授，硕士生导师，药物化学教研室主任，辽宁大学药物研究院秘书长。2015年毕业于中国科学院上海药物研究所，获得药物化学博士学位，主要从事抗肿瘤药物、抗凝血和抗感染药物的研究工作。主持国家自然科学基金项目1项；辽宁省科研项目4项，辽宁省教学改革项目2项，辽宁省一流课程1门；沈阳市科研项目1项；辽宁大学科研项目2项，辽宁大学教学改革项目及课程建设项目5项，横向项目1项；以骨干成员身份参加省级平台建设项目2项，省级科研项目6项，市级科研项目5项。以第一作者或通讯作者发表SCI论文19篇；已授权发明专利10余项。入选辽宁省“百千万人才工程”万人层次、沈阳市高层次人才（拔尖人才）、辽宁大学杰出青年人物和辽宁大学优秀共产党员。被聘为中国中医药信息学会中医临床药学分会常务理事、全国研究生教育评估监测专家库专家、全国本科毕业论文（设计）抽检评审专家库专家、中国药学会高级会员、东北科技专家、辽宁省科技厅计划项目专家、广东省科技厅计划项目专家、辽宁省企业科技特派员、CNKI（知网）评审专家、沈阳市科技项目评审专家、沈阳市知识产权专家。研究成果获评辽宁省自然科学学术成果奖、辽宁省职工技能大赛暨省总工会直属高校科技成果转化大赛决赛入围奖、沈阳市自然科学学术成果奖等。同时担任全国高校创业教育导师、辽宁大学本科教学名师、辽宁大学研究生教学名师、辽宁大学“三师团队”课程导师等，多次带领学生参加各种级别的大学生创新创业计划、“东富龙-国药工程杯”全国大学生制药工程设计竞赛、辽宁省普通高等学校本科大学生药苑论坛等并获奖。

研究生招生范围：药物化学、制药工程、药理学

联系方式：dingshi_destiny@163.com

一、主持的科研项目：

1.国家自然科学基金青年项目，基于晶体结构设计的，具有吡啶并[2,3-d]嘧啶结构的新型EGFR激酶抑制剂的合成及构效关系研究，21807055。

2.辽宁省科技计划联合计划（自然科学基金-面上项目），对C797S耐药突变具有高选择性的第四代EGFR抑制剂的设计、合成与抗肿瘤活性研究，2025-MSLH-291。

3.辽宁省教育厅高校基本科研项目（理工类），基于优势片段杂交策略进行设计的第四代 EGFR 激酶抑制剂的结构优化与药理活性研究，LJ212410140023。 

4.辽宁省自然科学基金计划面上项目，新型EGFR激酶抑制剂类抗非小细胞肺癌药物的设计、合成及药理活性研究，2022-MS-169。

5.辽宁省教育厅青年项目，新型LpxC抑制剂类抗菌剂的设计、合成和生物活性研究，LQN201709，2万元。

6.沈阳市青年科技人才省级项目配套奖励专项，新型EGFR激酶抑制剂类抗非小细胞肺癌药物的设计、合成及药理活性研究。 

7.辽宁大学 2024 年度基本科研项目（理工类），基于优势片段杂交策略进行设计的第四代 EGFR 激酶抑制剂的结构优化与药理活性研究，LJKLJ202401。

8.辽宁大学预申报项目，以吡啶并[2,3-d]嘧啶结构为母核的新型EGFR抑制剂的设计、合成及生物活性评价，LDGY2019002 

9.横向项目：白茶中儿茶素的分离提取及护肤功效测试。

三、主要学术论文（SCI收录）：

1.Shi Ding, Haotian Ding, Zhenzhen Zhan, Jinpeng Wang, Xinru Song, Yuanyu Wu, Xin Wang, Hanxue Zheng, Zhongyu Tang, Xiaoqing Peng, Shaoting Wu, Ju Liu*, Jiwei Shen*, Ye Chen*. Design, synthesis and biological evaluation of selective inhibitors against the L858R/T790 M/C797S mutant EGFR kinase based on the scaffold. European Journal of Medicinal Chemistry, 314 (2026) 118915. IF (2025) = 6.7.

2.Shi Ding, Yuanyu Wu, Bin Li, Xin Wang, Haotian Ding, Zhenzhen Zhan, Jiwei Shen, Rui Qi, Ziye Gao, Kai Yao, Riya Su, Hanxue Zheng, Zhongyu Tang, Ju Liu*, Ye Chen*. Design, synthesis and biological evaluation of imine-containing inhibitors against the triple-mutant EGFR kinases based on the scaffold of osimertinib. Bioorganic Chemistry, 160 (2025) 108474. IF（2025）= 5.1.

3.Hanrui Jiang, Nan Li, Ruosong Qin, Siyu Lin, Xuelian Wang, Chunyan Li, Jiwei Shen, Ye Chen, Ju Liu*, Shi Ding*（通讯作者）. Recent advances in Pyrazolo[3,4‑d]pyrimidine‑based dual inhibitors in the treatment of cancers. Molecular Diversity. https://doi.org/10.1007/s11030-025-11379-0. IF (2025) = 4.3.

4.Ju Liu, Junfeng Gao, Rui Jing, Siyu Lin, Yunpeng Zhou, Zhicheng Zhang, Enhui Han, Fanqi Jin, Yunlei Hou, Chunyan Li, Ye Chen,*, Jiwei Shen*, Shi Ding*（通讯作者）. Design, synthesis and biological evaluation of novel 4-(thieno[3,2-d] pyrimidin-4-yl)morpholine derivatives as potent antitumor agents. European Journal of Medicinal Chemistry, 293 (2025) 117671, IF (2025) = 6.7.

5.Ju Liu, Yadong Zhang, Yan Zhu, Lu Tian, Mingrui Tang, Jiwei Shen, Shi Ding* （通讯作者） and Ye Chen*. Research Progress on Small Molecules Inhibitors Targeting TRK Kinases. Current Medicinal Chemistry, 2023, 30, 1175-1192. IF (2022) = 3.5.

6.Shi Ding, Ziye Gao, Ziqiang Hu, Rui Qi, Xiangshan Zheng, Xiaoyong Dong, Mingjuan Zhang, Jiwei Shen, Tian Long, Yan Zhu, Lu Tian, Wenshan Song, Ruoqing Liu, Ying Li, Jiahuan Sun, Wenwen Duan, Ju Liu*, Ye Chen*. Design, synthesis and biological evaluation of novel osimertinib derivatives as reversible EGFR kinase inhibitors. European Journal of Medicinal Chemistry，238 (2022) 114492. IF (2022) = 6.7.

7.Shi Ding; Xiaoyong Dong; Ziye Gao; Xiangshan Zheng; Jingchao Ji; Mingjuan Zhang; Fang Liu; Shuang Wu; Min Li; Wenshan Song; Jiwei Shen; Wenwen Duan; Ju Liu*; Ye Chen*; Design, synthesis and biological evaluation of novel N-(3-amino-4-methoxyphenyl)acrylamide derivatives as selective EGFRL858R/T790M kinase inhibitors, Bioorganic Chemistry, 118 (2022) 105471. IF (2022) = 5.1.

8.Ju Liu, Fang Liu, Zhen Li, Chunyan Li, Shuang Wu, Jiwei Shen, Huan Wang, Siyuan Du, Hao Wei, Yunlei Hou, Shi Ding*（通讯作者）, Ye Chen*. Novel 4-phenoxypyridine derivatives bearing imidazole-4-carboxamide and 1,2,4-triazole-3-carboxamide moieties: Design, synthesis and biological evaluation as potent antitumor agents, Bioorganic Chemistry, 120 (2022) 105629. IF (2022) = 5.1.

9.LIU Ju, WU Shuang, WANG Huan, DU Si-Yuan，LI Zhen SHEN Ji-Wei, CHEN Ye*, DING Shi*（通讯作者）. Novel 2,4-Diarylaminopyrimidine Derivatives Containing Pyridine Moiety: Design, Synthesis, Crystal Structure and Biological Evaluation, Chinese Journal of Structural Chemistry, 2022, 41 (2): 132-140. IF (2022) = 2.2.

10.Xinghua Zhao, Shi Ding（共同第一作者）., Shengnan Li, Yang Wang, Mingjun Jiang, Ju Liu*, Ye Chen*, Construction of Gambogic Acid HPMA Copolymer Coupling Drug System and Study on Anti-tumor Activity, Current Drug Delivery, 2022, 19, 491-507. IF (2022) = 2.4.

11.Liu, Ju; Gong, Yilin; Shi, Jiantao; Hao, Xuechen; Wang, Yang; Zhou, Yunpeng; Hou, Yunlei; Liu, Yajing; Ding, Shi*（通讯作者）; Chen, Ye*; Design, synthesis and biological evaluation of novel N-[4-(2-fluorophenoxy)pyridin-2-yl] cyclopropanecarboxamide derivatives as potential c-Met kinase inhibitors. European Journal of Medicinal Chemistry. 194 (2020) 112244. IF (2020) = 6.5.

12.Liu, Ju; Li, Jun; Shi, Jian-tao; Li, Jie; Hao, Xue-chen; Song, Duang-zheng; Wang, Yang; Ding, Shi*（通讯作者）; Chen, Ye*. Synthesis and Biological Evaluation of Novel 4-Phenylaminobenzofuro [2,3-d]pyrimidine Derivatives. Journal of the Chemical Society of Pakistan. 2020, 42(04), 564-571. IF (2020) = 0.54.

13.Ding, Shi; Ji, Jing Chao; Zhang, Ming Juan; Yang, Yu She; Wang, Rui; Zhu, Xing Long; Wang, Li Hong; Zhong, Yi; Gao, Le; Lu, Man; Liu, Ju; Chen, Ye. Exploration of the structure-activity relationship and druggability of novel oxazolidinone-based compounds as Gram-negative antibacterial agents. Archiv der Pharmazie., 2019, e1900129. IF (2019) = 2.6.

14.Liu, Ju; Shi, Jian-Tao; Gong, Yi-Lin; Ding, Shi*（通讯作者）; Chen, Ye*. Synthesis, crystal and antiproliferative activity of 2-[2-(2-fluorobenzylidene) hydrazinyl]-4-(1-methyl-1H-indol-3-yl)thieno[3,2-d]pyrimidine. Molecular Crystals and Liquid Crystals. 2019, 692(1), 53–61. IF (2019) = 0.51.

15.Shi Jian Tao; Gong Yi Lin; Li Jun; Wang Yang; Chen Ye; Ding Shi*（通讯作者）; Liu Ju*. Synthesis, Structure and Biological Activity of 2-[2-(4-Fluorobenzylidene)hydrazinyl]-4-(1-methyl-1H-indol-3-yl)thieno[3,2-d]pyrimidine. Chinese Journal of Structural Chemistry, 2019, 38 (9): 1530~1536. IF (2019) = 0.74.

16.Shi Ding; Rui-Yang Dai; Wen-Ke Wang; Qiao Cao; Le-Fu Lan; Xian-Li Zhou; Yu-She Yang. Design, synthesis and structure-activity relationship evaluation of novel LpxC inhibitors as Gram-negative antibacterial agents. Bioorganic & Medicinal Chemistry Letters, 2018, 28(2): 94~102. IF (2018) = 2.4.

17.Xue, Tao; Ding, Shi（共同第一作者）; Guo, Bin; Chu, Wenjing; Wang, Hui; Yang, Yushe. Synthesis and structure-activity relationship studies of novel [6,6,5] tricyclic oxazolidinone derivatives as potential antibacterial agents. Bioorganic & Medicinal Chemistry Letters, 2015, 25(10): 2203~2210. IF (2015) = 2.5.

18.Shi Ding; Wen-Ke Wang; Qiao Cao; Wen-Jing Chu; Le-Fu Lan; Wen-Hao Hu; Yu-She Yang. Design, synthesis and biological evaluation of LpxC inhibitors with novel hydrophilic terminus. Chinese Chemical Letters, 2015, 26 (6): 763~767. IF (2015) = 2.0.

19.Xue, Tao; Ding, Shi（共同第一作者）; Guo, Bin; Zhou, Yuren; Sun, Peng; Wang, Heyao; Chu, Wenjing; Gong, Guoqing; Wang, Yinye; Chen, Xiaoyan; Yang, Yushe. Design, Synthesis, and Structure-Activity and Structure-Pharmacokinetic Relationship Studies of Novel [6,6,5] Tricyclic Fused Oxazolidinones Leading to the Discovery of a Potent, Selective, and Orally Bioavailable FXa Inhibitor. Journal of Medicinal Chemistry, 2014, 57(18): 7770~7791. IF (2014) = 5.4.